$256.20
▲ +1.1% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 2
● 23
▼ 0
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know
Overview
52-week range
$182
$245
100% of range
Avg surprise (last 2)
+2.9%
Avg reaction (last 1)
+3.2%
100% positive
Latest IV / EM
30%
EM ±1.8% · $253 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $0.39 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.10 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $2.97 | $2.89 | +2.8% | — | — | earnings |
| Fri Apr 25, 2025 | Mar/2025 | $2.46 | $2.39 | +2.9% | — | +3.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.88 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.77 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.77 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.00 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.14 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Jul 31, 2026 | Jun/2026 | BMO | $3.66 | $2.97 | +23.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.00B | — | $15.78B | $15.42B | $13.34B | — | $14.46B | $14.46B |
| Cost of revenue | $4.22B | — | $5.30B | $4.35B | $4.00B | — | $4.21B | $4.20B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $3.99B | — | $1.90B | $4.89B | $3.73B | — | $3.83B | $4.00B |
| Net income | $695M | — | $186M | $938M | $1.29B | — | $1.56B | $1.37B |
| EPS (diluted) | $0.39 | — | $0.10 | $0.52 | $0.72 | — | $0.88 | $0.77 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B |
| Inventory | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B |
| Total current assets | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B |
| Total assets | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B |